MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596411 | Name: Aspartic acid
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aspartic acid is one of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

Chemical Structure

Aspartic acid
Aspartic acid
CAS#56-84-8

Theoretical Analysis

MedKoo Cat#: 596411

Name: Aspartic acid

CAS#: 56-84-8

Chemical Formula: C4H7NO4

Exact Mass: 133.0375

Molecular Weight: 133.10

Elemental Analysis: C, 36.10; H, 5.30; N, 10.52; O, 48.08

Price and Availability

Size Price Availability Quantity
25g USD 250.00 2 Weeks
100g USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Aspartic acid; Aspatofort; Aminosuccinic acid; L(+)-Aminobernsteinsaeure; EC 200-291-6;
IUPAC/Chemical Name
L-aspartic acid
InChi Key
CKLJMWTZIZZHCS-REOHCLBHSA-N
InChi Code
InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1
SMILES Code
N[C@@H](CC(O)=O)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
L-Aspartic acid is is an amino acid, shown to be a suitable prodrug for colon-specific drug delivery.
In vitro activity:
Linear scratch wounds were made on confluent sheets of HaCATs, and the percentage closure of wound at 6, 12 and 24 h was calculated based on image analysis. Results showed that untreated cells sealed 24% of the wounded area. Treatment with A-A-A (Aspartic acid) boosted wound healing with as much as 33% of the wound closed after 24 h (Fig. 1), which means that A-A-A boosts the tissue regenerative activity by 50% compared to untreated cells. Retinol treatment showed similar activity to A-A-A at the same concentration (data not shown). These results suggest that A-A-A exhibits wound healing activity. Reference: Int J Cosmet Sci. 2015 Oct;37 Suppl 1:15-20. https://pubmed.ncbi.nlm.nih.gov/26139465/
In vivo activity:
In the D-Asp (Aspartic acid) + EDS treated rats, it was appreciable a picture of the histological features that was no dissimilar to that of the control (Figure 2C). In fact, LC in the interstitial compartment were observed (asterisk, Figure 2C) and the organization of the adjacent germinal compartment was quite like that observed in the control testis. The above data were confirmed by the analysis of three different morphometric parameters, which showed that the epithelium thickness and diameter, as well as the percentage of tubular lumen occupied by SPZ were significantly lower in EDS-treated group as compared to the controls (Table 1). These results not only confirmed, once again, that EDS deadly action is specific for the interstitial LC, affecting the normal spermatogenesis, but also that the pre-treatment with D-Asp ameliorated its harmful effects on the hormonal and histological status. Reference: Animals (Basel). 2021 Jan; 11(1): 133. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827869/
Solvent mg/mL mM
Solubility
DMSO 8.2 61.38
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 133.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Gillbro JM, Lundahl M, Westman M, Baral R, Al-Bader T, Mavon A. Structural activity relationship analysis (SAR) and in vitro testing reveal the anti-ageing potential activity of acetyl aspartic acid. Int J Cosmet Sci. 2015 Oct;37 Suppl 1:15-20. doi: 10.1111/ics.12253. PMID: 26139465. 2. Chandrashekar KN, Muralidhara. Oxidative alterations induced by D-aspartic acid in prepubertal rat testis in vitro: a mechanistic study. Theriogenology. 2008 Jul 1;70(1):97-104. doi: 10.1016/j.theriogenology.2008.02.004. Epub 2008 Apr 24. PMID: 18439665. 3. Venditti M, Romano MZ, Aniello F, Minucci S. Preliminary Investigation on the Ameliorative Role Exerted by D-Aspartic Acid in Counteracting Ethane Dimethane Sulfonate (EDS) Toxicity in the Rat Testis. Animals (Basel). 2021 Jan 8;11(1):133. doi: 10.3390/ani11010133. PMID: 33435542; PMCID: PMC7827869. 4. Ichikawa S, Gohda T, Murakoshi M, Li Z, Adachi E, Koshida T, Suzuki Y. Aspartic acid supplementation ameliorates symptoms of diabetic kidney disease in mice. FEBS Open Bio. 2020 Jun;10(6):1122-1134. doi: 10.1002/2211-5463.12862. Epub 2020 May 18. PMID: 32301275; PMCID: PMC7262904.
In vitro protocol:
1. Gillbro JM, Lundahl M, Westman M, Baral R, Al-Bader T, Mavon A. Structural activity relationship analysis (SAR) and in vitro testing reveal the anti-ageing potential activity of acetyl aspartic acid. Int J Cosmet Sci. 2015 Oct;37 Suppl 1:15-20. doi: 10.1111/ics.12253. PMID: 26139465. 2. Chandrashekar KN, Muralidhara. Oxidative alterations induced by D-aspartic acid in prepubertal rat testis in vitro: a mechanistic study. Theriogenology. 2008 Jul 1;70(1):97-104. doi: 10.1016/j.theriogenology.2008.02.004. Epub 2008 Apr 24. PMID: 18439665.
In vivo protocol:
1. Venditti M, Romano MZ, Aniello F, Minucci S. Preliminary Investigation on the Ameliorative Role Exerted by D-Aspartic Acid in Counteracting Ethane Dimethane Sulfonate (EDS) Toxicity in the Rat Testis. Animals (Basel). 2021 Jan 8;11(1):133. doi: 10.3390/ani11010133. PMID: 33435542; PMCID: PMC7827869. 2. Ichikawa S, Gohda T, Murakoshi M, Li Z, Adachi E, Koshida T, Suzuki Y. Aspartic acid supplementation ameliorates symptoms of diabetic kidney disease in mice. FEBS Open Bio. 2020 Jun;10(6):1122-1134. doi: 10.1002/2211-5463.12862. Epub 2020 May 18. PMID: 32301275; PMCID: PMC7262904.
1: Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018 Mar 15;3:CD011481. doi: 10.1002/14651858.CD011481.pub2. Review. PubMed PMID: 29543325. 2: Fujii N, Takata T, Fujii N, Aki K, Sakaue H. D-Amino acids in protein: The mirror of life as a molecular index of aging. Biochim Biophys Acta. 2018 Jul;1866(7):840-847. doi: 10.1016/j.bbapap.2018.03.001. Epub 2018 Mar 10. Review. PubMed PMID: 29530565. 3: Wang D, De Vivo D. Pyruvate Carboxylase Deficiency. 2009 Jun 2 [updated 2018 Mar 1]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from http://www.ncbi.nlm.nih.gov/books/NBK6852/ PubMed PMID: 20301764. 4: Zhi D, Bai Y, Yang J, Cui S, Zhao Y, Chen H, Zhang S. A review on cationic lipids with different linkers for gene delivery. Adv Colloid Interface Sci. 2018 Mar;253:117-140. doi: 10.1016/j.cis.2017.12.006. Epub 2017 Dec 26. Review. PubMed PMID: 29454463. 5: Mori T, Sawaguchi T. [Underlying Mechanisms of Methamphetamine-Induced Self-Injurious Behavior and Lethal Effects in Mice]. Nihon Eiseigaku Zasshi. 2018;73(1):51-56. doi: 10.1265/jjh.73.51. Review. Japanese. PubMed PMID: 29386447. 6: Raniga K, Liang C. Interferons: Reprogramming the Metabolic Network against Viral Infection. Viruses. 2018 Jan 13;10(1). pii: E36. doi: 10.3390/v10010036. Review. PubMed PMID: 29342871; PubMed Central PMCID: PMC5795449. 7: Rampa A, Gobbi S, Concetta Di Martino RM, Belluti F, Bisi A. Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review. Curr Top Med Chem. 2017;17(31):3361-3369. doi: 10.2174/1568026618666180112161406. Review. PubMed PMID: 29332582. 8: Coley AA, Gao WJ. PSD95: A synaptic protein implicated in schizophrenia or autism? Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:187-194. doi: 10.1016/j.pnpbp.2017.11.016. Epub 2017 Nov 21. Review. PubMed PMID: 29169997; PubMed Central PMCID: PMC5801047. 9: Song L, Chen Y, Du Y, Wang X, Guo X, Dong J, Xiao D. Saccharomyces cerevisiae proteinase A excretion and wine making. World J Microbiol Biotechnol. 2017 Nov 9;33(11):210. doi: 10.1007/s11274-017-2361-z. Review. PubMed PMID: 29124367. 10: Venkatesan A, Adatia K. Anti-NMDA-Receptor Encephalitis: From Bench to Clinic. ACS Chem Neurosci. 2017 Dec 20;8(12):2586-2595. doi: 10.1021/acschemneuro.7b00319. Epub 2017 Nov 7. Review. PubMed PMID: 29077387. 11: Igarashi H, Ueki S, Ohno K, Ohkubo M, Suzuki Y. Magnetic Resonance Imaging of Neurotransmitter-Related Molecules. J Nippon Med Sch. 2017;84(4):160-164. doi: 10.1272/jnms.84.160. Review. PubMed PMID: 28978895. 12: Choudhary AK, Pretorius E. Revisiting the safety of aspartame. Nutr Rev. 2017 Sep 1;75(9):718-730. doi: 10.1093/nutrit/nux035. Review. PubMed PMID: 28938797. 13: Jansson ET. Strategies for analysis of isomeric peptides. J Sep Sci. 2018 Jan;41(1):385-397. doi: 10.1002/jssc.201700852. Epub 2017 Oct 10. Review. PubMed PMID: 28922569. 14: Barbagallo M, Vitaliti G, Pavone P, Romano C, Lubrano R, Falsaperla R. Pediatric Autoimmune Encephalitis. J Pediatr Neurosci. 2017 Apr-Jun;12(2):130-134. doi: 10.4103/jpn.JPN_185_16. Review. PubMed PMID: 28904568; PubMed Central PMCID: PMC5588635. 15: Moriishi K. The potential of signal peptide peptidase as a therapeutic target for hepatitis C. Expert Opin Ther Targets. 2017 Sep;21(9):827-836. doi: 10.1080/14728222.2017.1369959. Epub 2017 Aug 22. Review. PubMed PMID: 28820612. 16: Moussa CE. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. Expert Opin Investig Drugs. 2017 Oct;26(10):1131-1136. doi: 10.1080/13543784.2017.1369527. Epub 2017 Aug 23. Review. PubMed PMID: 28817311. 17: Sun Y, Kang C, Liu F, Zhou Y, Luo L, Qiao H. RGD Peptide-Based Target Drug Delivery of Doxorubicin Nanomedicine. Drug Dev Res. 2017 Sep;78(6):283-291. doi: 10.1002/ddr.21399. Epub 2017 Aug 16. Review. PubMed PMID: 28815721. 18: MacPherson REK. Filling the void: a role for exercise-induced BDNF and brain amyloid precursor protein processing. Am J Physiol Regul Integr Comp Physiol. 2017 Nov 1;313(5):R585-R593. doi: 10.1152/ajpregu.00255.2017. Epub 2017 Aug 16. Review. PubMed PMID: 28814391; PubMed Central PMCID: PMC5792152. 19: McGillewie L, Ramesh M, Soliman ME. Sequence, Structural Analysis and Metrics to Define the Unique Dynamic Features of the Flap Regions Among Aspartic Proteases. Protein J. 2017 Oct;36(5):385-396. doi: 10.1007/s10930-017-9735-9. Review. PubMed PMID: 28762197. 20: Mentrup T, Loock AC, Fluhrer R, Schröder B. Signal peptide peptidase and SPP-like proteases - Possible therapeutic targets? Biochim Biophys Acta. 2017 Nov;1864(11 Pt B):2169-2182. doi: 10.1016/j.bbamcr.2017.06.007. Epub 2017 Jun 15. Review. PubMed PMID: 28624439.